Menarini licenses new gout treatment from Ipsen
This article was originally published in Scrip
Menarini is to bring to market in Europe the first new treatment for chronic hyperuricaemia in gout in 40 years under a licensing agreement with Ipsen. The Italian firm plans to launch Adenuric (febuxostat) in the first markets early next year.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.